VVOS

Business Context and Reporting Period

Company: Vivos Therapeutics, Inc. (VVOS)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2025
Business Overview: Vivos is a medical technology company focused on non-surgical treatments for obstructive sleep apnea (OSA) using proprietary oral appliances ("The Vivos Method"). In 2025, the company executed a strategic pivot from a legacy dentist-focused enrollment model to a medical-provider focused model involving the acquisition and management of sleep centers. The primary catalyst for this shift was the June 2025 acquisition of The Sleep Center of Nevada (SCN), marking the company's entry into direct patient care and diagnostic services.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Composition Shift: Service revenue increased by 53% ($3.8 million) driven by $4.8 million in diagnostic testing and $2.0 million in treatment revenue from the newly acquired SCN. Conversely, product revenue declined 18% due to reduced sales to legacy VIP dentists and increased discounting.
• Expense Surge: General and Administrative (G&A) expenses jumped 55% ($9.8 million increase) primarily due to $6.7 million in costs associated with operating SCN and related treatment centers. Depreciation and amortization more than doubled ($0.7 million increase) due to new assets from the acquisition.
• Liquidity Deterioration: Cash and cash equivalents decreased by $4.2 million to $2.0 million. Net cash used in operating activities increased to $15.3 million from $12.7 million. The company incurred significant new debt ($8.3 million Streeterville Note and $2.1 million Avondale Note) to fund the SCN acquisition.
• Going Concern Warning: Management has raised substantial doubt about the company's ability to continue as a going concern, citing an accumulated deficit of $125.4 million and cash levels insufficient to fund operations for the next 12 months without additional financing.

Guidance, Outlook, and Risks

• Strategic Outlook: Management expects the SCN acquisition and the new medical-provider model to drive future revenue growth and eventually achieve cash flow positivity. The company aims to replicate the SCN model through further acquisitions or management service organization (MSO) agreements.
• Financing Needs: The company explicitly states it requires additional capital to fund operations and meet Nasdaq listing requirements (specifically the $2.5 million stockholders' equity minimum, which it currently fails to meet). Recent financings include a January 2026 warrant inducement and a March 2026 PIPE offering.
• Key Risks:
  • Liquidity: Insufficient cash to fund operations for the next 12 months without further equity or debt financing.
  • Integration: Risks associated with integrating SCN, including staffing shortages, insurance credentialing delays, and the ability to scale the new business model.
  • Regulatory: Compliance with corporate practice of medicine laws and FDA regulations regarding the transition to a "Manufacturer" designation.
  • Market: Dependence on third-party insurance reimbursement rates and the willingness of patients to pay out-of-pocket.

Investor Verification Checklist

• Cash Runway: Verify the sufficiency of the $2.0 million cash balance against the $15.3 million annual operating burn rate and upcoming debt service obligations.
• Nasdaq Compliance: Monitor the company's progress in regaining compliance with the $2.5 million stockholders' equity requirement to avoid delisting.
• SCN Integration Metrics: Track the ramp-up of "Sleep Optimization" teams, insurance credentialing status, and patient volume at SCN to validate the new revenue model.
• Debt Covenants: Review the terms of the Streeterville and Avondale notes, specifically redemption rights and default interest rates, to assess refinancing risk.
• Legacy Revenue Decline: Assess the rate of decline in legacy VIP enrollment revenue and whether the new service revenue is growing fast enough to offset it.